Business Context and Reporting Period
Company: Omeros Corporation
Filing Type: Form 8-K (Current Report)
Date of Report: March 23, 2018
Subject: Item 8.01 Other Events regarding legislative changes affecting Medicare reimbursement.
Key Financial Metrics
This filing is a current report regarding a regulatory event and does not contain financial statements, revenue figures, profit data, cash flow, margins, debt levels, or liquidity metrics.
Material Changes
The filing reports a material change in the regulatory environment affecting the company's primary product, OMIDRIA (phenylephrine and ketorolac intraocular solution 1%/0.3%):
- Legislative Action: President Trump signed the Consolidated Appropriations Act, 2018 on March 23, 2018.
- Reimbursement Extension: A provision in the Act extends pass-through reimbursement status for OMIDRIA for an additional two years.
- Effective Period: October 1, 2018, through September 30, 2020.
- Payment Rate: During this period, the drug will receive separate payment at a rate of Average Sales Price (ASP) plus 6%.
- Context: Without this extension, the drug's pass-through status had expired on December 31, 2017, and it was included in packaged procedural payments as of January 1, 2018.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms that OMIDRIA is one of the specific drugs qualifying for the reimbursement extension, aligning its payment structure with almost all other physician-administered drugs that come off pass-through status.
Risks and Contingencies: The filing does not explicitly list new risks but implies that the prior risk of losing separate reimbursement status has been mitigated for the specified two-year period.
Unusual Items: None reported beyond the legislative event.
Investor Verification Checklist
- Verify the specific impact of the ASP + 6% reimbursement rate on projected revenue for the 2018-2020 period.
- Confirm the exact date the extension becomes effective (October 1, 2018) and the transition from packaged payments.
- Review subsequent filings for any changes to the ASP calculation or further legislative updates affecting the 2020 expiration.
- Assess the competitive landscape for intraocular solutions under the new reimbursement framework.